Evidence map›Paper›PMID 38941567›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Taletrectinib: TRUST in the Continued Evolution of Treatments for

Sarah Waliany, Jessica J Lin

Abstract readEditorialComment
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.International journal of molecular sciences · 2025
    Review
  4. Cancer drug resistance (Alhambra, Calif.) · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sarah WalianyCancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-5960-8801
Jessica J LinCancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-7373-3916

Funding

Training Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6M
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, Jessica Jiyeong Lin · 2012 to 2026
$5.5M
NCI NIH HHS R01 CA164273NCI NIH HHS T32 CA071345
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lung NeoplasmsProtein-Tyrosine KinasesProto-Oncogene ProteinsCarcinoma, Non-Small-Cell LungHumansOncogene Proteins, FusionOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, human

Identifiers

PMID38941567
PMCPMC11286343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.